TABLE 3.
Association of WML% with equol‐producing status 6 to 9 years before the imaging study (structural brain magnetic resonance imaging; %)
| Non‐producers (n = 45) | Low producers (n = 23) | High producers (n = 23) | Trend P | |
|---|---|---|---|---|
| Model I | 1.19 (0.97, 1.49) | 0.89 (0.67, 1.17) | 0.58 (0.44, 0.72) | <.01 |
| Model II | 1.16 (0.94, 1.42) | 0.92 (0.69, 1.23) | 0.59 (0.44, 0.78) | <.01 |
| Model III | 1.13 (0.92, 1.37) | 0.93 (0.69, 1.12) | 0.63 (0.48, 0.83) | <.01 |
| Model IV | 1.13 (0.93, 1.38) | 0.88 (0.67, 1.15) | 0.64 (0.49, 0.85) | <.01 |
| Model V | 1.11 (0.93, 1.38) | 0.88 (0.67, 1.17) | 0.65 (0.49, 0.85) | <.01 |
Abbreviation: WML%, white matter lesion volume normalized to the total brain volume.
Notes: Values are expressed as adjusted mean (95% confidence interval).
Model I: adjusted for age, sex, and body mass index; Model II: further adjusted for hypertension, diabetes, dyslipidemia, and coronary heart disease; Model III: further adjusted for apolipoprotein ε4 and years of education; Model IV: additionally adjusted for daidzein; Model V: adjusted for genistein instead of daidzein to Model III.